The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma.

Autor: Narukawa, Tsukasa^1,2 (AUTHOR) tnarukaw@koto.kpu-m.ac.jp, Yasuda, Shusuke¹ (AUTHOR) m-hori@koto.kpu-m.ac.jp, Horinaka, Mano¹ (AUTHOR) ktaniguc@koto.kpu-m.ac.jp, Taniguchi, Keiko¹ (AUTHOR) miemori@koto.kpu-m.ac.jp, Tsujikawa, Takahiro³ (AUTHOR) tu-ji@koto.kpu-m.ac.jp, Morita, Mie¹ (AUTHOR) tsakai@koto.kpu-m.ac.jp, Ukimura, Osamu² (AUTHOR), Sakai, Toshiyuki¹ (AUTHOR)

Publikováno v: Cancers. Dec2024, Vol. 16 Issue 23, p4058. 16p.

PO-455 Epigenetic insights: resminostat regulates targets associated with the pathogenesis of cutaneous T cell lymphoma (CTCL)

Autor: Bretz, A.C., Wulff, T., Parnitzke, U., Schrepfer, S., Kronthaler, K., Borgmann, M.

Publikováno v: In ESMO Open 30 June-3 July 2018 3 Supplement 2:A200-A201

APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis.

Autor: Fan, Zhiwei^1,2,3 (AUTHOR), Liu, Yiting^1,2,4 (AUTHOR), Wang, Xuehai² (AUTHOR), Xu, Yuting¹ (AUTHOR), Huang, Ruiyao² (AUTHOR), Shi, Weijian² (AUTHOR), Qu, Yi² (AUTHOR), Ruan, Jialing² (AUTHOR), Zhou, Chu² (AUTHOR), Zhao, Xinyuan² (AUTHOR) zhaoxinyuan@ntu.edu.cn, Liu, Lei¹ (AUTHOR) liulei19920123@163.com

Publikováno v: BMC Cancer. 8/26/2024, Vol. 24 Issue 1, p1-18. 18p.

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).

Autor: Bretz AC; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany., Parnitzke U; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany., Kronthaler K; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany., Dreker T; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany., Bartz R; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany., Hermann F; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany., Ammendola A; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany., Wulff T; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany., Hamm S; 4SC AG, Fraunhoferstr. 22, 82152, Planegg-Martinsried, Germany. svetlana.hamm@4sc.com.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Nov 08; Vol. 7 (1), pp. 294. Date of Electronic Publication: 2019 Nov 08.

285 - Resminostat, a phase II clinical HDAC inhibitor, sensitizes tumor cells for NK cell response and synergizes with ADCC therapy

Autor: Hamm, S., Parnitzke, U., Kronthaler, K., Wulff, T.

Publikováno v: In European Journal of Cancer December 2016 69 Supplement 1:S94-S94